Wonsart-Amh Tablet is a combination antihypertensive medication containing Telmisartan 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg. This formulation is designed to effectively manage hypertension by utilizing three complementary mechanisms of action. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance and lowering blood pressure. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium influx into vascular smooth muscle cells, contributing to decreased arterial pressure. Hydrochlorothiazide, a thiazide diuretic, facilitates the excretion of sodium and water, reducing plasma volume and further aiding in blood pressure control. The combination of these agents provides a synergistic effect, improving efficacy in patients with hypertension inadequately controlled by monotherapy or dual therapy. Wonsart-Amh is indicated for the treatment of essential hypertension and may help reduce the risk of cardiovascular events associated with high blood pressure. It should be used under medical supervision, with regular monitoring of blood pressure, renal function, and electrolyte levels to minimize potential adverse effects such as hypotension, electrolyte imbalance, or renal impairment. This tablet is contraindicated in patients with hypersensitivity to any component and should be used cautiously in those with comorbid conditions.